{"filing":{"accession_number":"0001683168-26-007090","cik":"0001402328","ticker":"SBFMW","company_name":"Sunshine Biopharma Inc.","form":"8-K","filing_date":"2026-09-11","report_date":"2026-09-11","primary_document":"sunshine_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316826007090/sunshine_8k.htm"},"events":[{"id":33011,"run_id":30342,"accession_number":"0001683168-26-007090","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The filing discloses that recent sales of common stock under an at-the-market offering have triggered a reduction in the exercise price of outstanding Series B Warrants to $1.2046. This reflects dilutive equity issuance activity that materially affects warrant holders and existing shareholders through price adjustment mechanics. While the disclosure is brief and Item 8.01 is used rather than Item 3.02, the substance is a capital raise via ATM offering with warrant repricing consequences.","company_name":"Sunshine Biopharma Inc.","ticker":"SBFMW","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36336,"accession_number":"0001683168-26-007090","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses that recent sales of common stock under an at-the-market offering have triggered a reduction in the exercise price of outstanding Series B Warrants to $1.2046. This reflects dilutive equity issuance activity that materially affects warrant holders and existing shareholders through price adjustment mechanics. While the disclosure is brief and Item 8.01 is used rather than Item 3.02, the substance is a capital raise via ATM offering with warrant repricing consequences.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T21:01:58.405923+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36336,"accession_number":"0001683168-26-007090","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses that recent sales of common stock under an at-the-market offering have triggered a reduction in the exercise price of outstanding Series B Warrants to $1.2046. This reflects dilutive equity issuance activity that materially affects warrant holders and existing shareholders through price adjustment mechanics. While the disclosure is brief and Item 8.01 is used rather than Item 3.02, the substance is a capital raise via ATM offering with warrant repricing consequences.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T21:01:58.405923+00:00","company_name":"Sunshine Biopharma Inc.","ticker":"SBFMW","filing_date":"2026-09-11"}]}